VistaGen Therapeutics
Biopharmaceutical company developing innovative product candidates for patients with diseases and disorders involving the cns.
Launch date
Employees
Market cap
CAD118m
Enterprise valuation
(CAD27m) (Public information from Sep 2024)
Share price
$3 VTGN
San Francisco California (HQ)
Authorizing premium user...